Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Scientists at Sanford Burnham Prebys have discovered that boosting a protein called SORLA significantly reduces toxic tau tangles, protects brain cell connections, and limits brain shrinkage in mice. The flip side? Removing SORLA made neurodegeneration worse. Published in Science Advances, the findings suggest that enhancing the brain's own defenses — or repurposing existing drugs — could open new doors for treating Alzheimer's and related dementias.
Scientists have identified a promising new target in the fight against Alzheimer's disease: a protein called SORLA. Researchers at Sanford Burnham Prebys found that increasing SORLA levels in mice reduced toxic tau tangles, curbed brain shrinkage, and preserved the synaptic connections critical for memory and learning. When SORLA was removed entirely, the damage got significantly worse — underscoring just how vital this protein is to brain health.
SORLA was already known to help limit amyloid-beta buildup, one of Alzheimer's hallmarks. This new study, published in Science Advances, reveals it also combats tau pathology — the other major driver of the disease. The protein works by reducing abnormal tau modifications, blocking the spread of toxic tau "seeds," and suppressing harmful changes in glial cells that support neurons.
One particularly exciting finding: the absence of SORLA triggered overactivation of plexin-B receptors — and drugs targeting this receptor family already exist, hinting at a potential repurposing opportunity.
Key Takeaways
Why it matters: With no disease-modifying treatments for most tauopathies, SORLA represents a fresh therapeutic angle — one that could lead to new drugs or repurposed therapies for millions living with Alzheimer's and related dementias.